Giulia Pasello

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang et al. · The Lancet Oncology · 2020 · 621 citations · Full text

Virus Epidemiology, Medicine, Covid-19 Pandemic +12

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso et al. · The Oncologist · 2019 · 224 citations

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Paolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri et al. · Journal of Clinical Oncology · 2017 · 169 citations

Cancer Management, Thymic Carcinoma Previously, Immunology +20

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes

Laura Bonanno, Alberto Pavan, Maria Vittoria Dieci et al. · European Journal of Cancer · 2018 · 112 citations

Cancer Immunosurveillance, Immune Microenvironment, Pd-l1 Expression +9